Extent and Risks of Antipsychotic Off-Label Use in Children and Adolescents in Germany Between 2004 and 2011

• Published in: Journal of child and adolescent psychopharmacology Vol. 27; no. 9; pp. 806 - 813
• Main Authors: Schröder, Carsten, Dörks, Michael, Kollhorst, Bianca, Blenk, Tilo, Dittmann, Ralf W., Garbe, Edeltraut, Riedel, Oliver
• Format: Journal Article
• Language: English
• Published: United States Mary Ann Liebert, Inc 01.11.2017
• Subjects: Adolescents; Antipsychotic Agents - therapeutic use; Antipsychotics; Attention Deficit Disorder with Hyperactivity - drug therapy; Child; Child & adolescent psychiatry; Children; Female; Germany; Humans; Male; Off-Label Use; Patient safety; Pediatrics; Poisoning; Practice Patterns, Physicians' - statistics & numerical data; Prescriptions; Psychopharmacology; Psychotropic drugs; Risk Factors; Studies; Teenagers; antipsychotics; off-label use; risks; adolescents; children
• ISSN: 1044-5463; 1557-8992; 1557-8992
• DOI: 10.1089/cap.2016.0202

Only little is known about antipsychotic (AP) off-label use (OLU) in pediatric populations. It was the aim of this study to examine the frequency as well as the risks of off-label AP use in underaged patients. To calculate the frequency of off-label AP prescriptions for the years 2004-2011, we used claims data of more than two million minors aged 0-17 years. Off-label prescriptions were analyzed with regard to type of OLU, physician specialty, and underlying diagnoses. Incidence rates of selected adverse events were calculated for on-label as well as for OLU. The risk of poisoning associated with on- or OLU was assessed in a nested case-control study. The annual share of pediatric AP users with off-label prescriptions varied between 52.3% and 71.1%. OLU by indication (42.8%-66.5%) was the most common type of OLU. Of the subjects with OLU by indication, 52.5% had a diagnosis of hyperkinetic disorder. Adverse events were scarce (incidence rates between 0.8 and 8.6 per 10,000 person-years), and no significant difference was observed between on- and OLU. Because of their frequent use in hyperkinetic disorder patients, APs are commonly prescribed off-label for minors. Since OLU by contraindication was rare and the risk of the adverse events under study was similarly small for on- and OLU, this is not necessarily an indication for inappropriate treatment. It rather indicates that further randomized studies are needed to examine efficacy and safety of pediatric AP use in this indication.